Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis

BACKGROUND: This study evaluated the hemoglobin dose response, other efficacy measures and safety of daprodustat, an orally administered, hypoxia-inducible factor prolyl hydroxylase inhibitor in development for anemia of chronic kidney disease. METHODS: Participants (n = 216) with baseline hemoglobi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Kidney J
Asıl Yazarlar: Meadowcroft, Amy M, Cizman, Borut, Holdstock, Louis, Biswas, Nandita, Johnson, Brendan M, Jones, Delyth, Nossuli, A Kaldun, Lepore, John J, Aarup, Michael, Cobitz, Alexander R
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2018
Konular:
Anemia
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6366140/
https://ncbi.nlm.nih.gov/pubmed/30746141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfy014
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller